Currently out of the existing stock ratings of Phil Nadeau, 111 are a BUY (90.98%), 11 are a HOLD (9.02%).

Phil Nadeau

Work Performance Price Targets & Ratings Chart

Analyst Phil Nadeau, currently employed at TD COWEN, carries an average stock price target met ratio of 64.44% that have a potential upside of 34.4% achieved within 456 days. Previously, Phil Nadeau worked at COWEN.

Phil Nadeau’s has documented 247 price targets and ratings displayed on 27 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NBIX, Neurocrine Biosciences at 05-Dec-2025.

Wall Street Analyst Phil Nadeau

Analyst best performing recommendations are on IMMU (IMMUNOMEDICS).
The best stock recommendation documented was for IMMU (IMMUNOMEDICS) at 4/1/2020. The price target of $30 was fulfilled within 28 days with a profit of $19.86 (195.86%) receiving and performance score of 69.95.

Average potential price target upside

of $47.17 (70.86%) on GILD (GILEAD SCIENCES).
of $44.37 (39.36%) on ALXN (ALEXION PHARMACEUTICALS).
of $45.3 (14.93%) on BIIB (BIOGEN).

ACOR Acorda Therapeutics APLS Apellis Pharmaceuticals BMRN Biomarin Pharmaceutical DVAX Dynavax Technologies GWPH GW Pharmaceuticals plc IMMU Immunomedics NBIX Neurocrine Biosciences VRTX Vertex Pharmaceuticals GNCA Genocea Biosciences LJPC La Jolla Pharmaceutical Co REGN Regeneron Pharmaceuticals GILD Gilead Sciences BIIB Biogen TCDA Tricida AURA Aura Biosciences FREQ Frequency Therapeutics GRPH Graphite Bio ONCE Spark Therapeutics PHAS PhaseBio Pharmaceuticals UTHR United Therapeutics ZFGN Zafgen RYTM Rhythm Pharmaceuticals ALXN Alexion Pharmaceuticals ATXS Astria Therapeutics CATB Catabasis Pharmaceuticals LRMR Larimar Therapeutics PTLA Portola Pharmaceuticals

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score